Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the

Amarin Announces Publication of Additional Inflammatory Marker Data From
MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of
Cardiovascular Drugs

Reductions in Several Inflammatory Markers Shown in Hypertriglyceridemic
Patients

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that additional data from its pivotal MARINE and
ANCHOR Phase 3 clinical trials are now available electronically through PubMed
(available at: http://www.ncbi.nlm.nih.gov/pubmed/23325450) and are expected
to be published in the print issue of the American Journal of Cardiovascular
Drugs in February 2013.

The publication, titled "Icosapent Ethyl, a Pure Ethyl Ester of
Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the
MARINE and ANCHOR Studies," is co-authored by Harold E. Bays, M.D. (Medical
Director, Louisville Metabolic and Atherosclerosis Research Center), Christie
M. Ballantyne, M.D. (Baylor College of Medicine and the Methodist DeBakey
Heart and Vascular Center, Houston, TX), and Amarin scientists. The
publication reports the effects of Vascepa^® (icosapent ethyl) capsules, alone
and in combination with statin therapies, on inflammatory markers associated
with cardiovascular disease and atherosclerosis in hypertriglyceridemic
patients. In addition to the previously reported favorable lipid effects of
Vascepa on hypertriglyceridemic patients in the MARINE and ANCHOR studies,
this newly published analysis of these studies shows that Vascepa 4g/day
significantly decreased levels of several inflammatory markers relative to
placebo, including oxidized low-density lipoprotein (Ox-LDL),
lipoprotein-associated phospholipase A2 (Lp-PLA[2]), and high sensitivity
C-reactive protein (hsCRP).

"Statins are known to decrease hsCRP levels, and subjects in both MARINE and
ANCHOR who received statin therapy were on stable therapy prior to
administration of Vascepa," stated Steve Ketchum, Ph.D., President of Research
and Development for Amarin. "The effects of Vascepa on inflammatory markers
described in this publication were in addition to effects already achieved
with statins.It is of interest that in ANCHOR, Vascepa decreased hsCRP more
in higher-efficacy statin regimens, which is consistent with the previously
reported ANCHOR findings of higher triglyceride reductions in patients with
higher-efficacy statin regimens."

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about the potential efficacy, safety and therapeutic benefits of
Amarin'sproduct candidates, Amarin's clinical trial results, and the timing
of publication, including statements about the clinical importance of certain
biomarkers and the impact of Vascepa on such biomarkers. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those described or projected herein include uncertainties
associated generally with research and development, clinical trials and
related regulatory approvals, including the risk that historical clinical
trial results may not be predictive of future results in replicated in larger
patient populations. A further list and description of these risks,
uncertainties and other risks associated with an investment inAmarincan be
found inAmarin'sfilings with theU.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q.Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Amarin'sproduct candidates are in various stages of development and are not
available for sale or use outside of approved clinical trials. Nothing in this
press release should be construed as promoting the use of such product
candidates outside approved indications.

CONTACT: Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.